Literature DB >> 9610688

Current clinical trial design issues in hormone-refractory prostate carcinoma. Consensus Panel.

N J Vogelzang, E D Crawford, A Zietman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9610688     DOI： 10.1002/(sici)1097-0142(19980601)82:11<2093::aid-cncr3>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

1.  A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).

Authors:  Joyce M van Dodewaard-de Jong; John M H de Klerk; Haiko J Bloemendal; Bart P J van Bezooijen; Marie J de Haas; Richard H Wilson; Joe M O'Sullivan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-27       Impact factor: 9.236

Review 2.  [Therapy of hormone-refractory prostate cancer].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2005-12       Impact factor: 0.639

Review 3.  [Treatment options for hormone-refractory prostate cancer].

Authors:  A Heidenreich; C H Ohlmann
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

4.  Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.

Authors:  Rubén Algarra; Mateo Hevia; Antonio Tienza; Imanol Merino; José María Velis; Javier Zudaire; José Enrique Robles; Ignacio Pascual
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.